Market News
Global Plasma Protein Therapeutic Market- Recent Developments
Product Approval and Launch
- In October 2022, Grifols, a global leader in plasma medicines, announced that its drug TAVLESSE (fostamatinib), used to treat chronic immune thrombocytopenia (ITP) in adult patients refractory to other treatments, is now recommended by the National Institute for Health and Care Excellence (NICE)
- In March 2022, Terumo Blood and Cell Technologies, a company specializing in medical devices, received approval from the U.S. Food and Drug Administration (FDA) for its innovative plasma collection system known as the Rika Plasma Donation System (Rika). This state-of-the-art automated system is designed to enhance the experience for both donors and plasma center staff, signaling a new era in plasma donation technology.
Business Development Activities by Market Players
- In October 2022, Grifols, a biopharmaceutical company, announced the official opening of its advanced production facility located in Ireland. This strategic expansion aims to address the increasing international demand for plasma-derived medicines. With this move, the production capacity of Grifols' ALBUTEIN FlexBag—a novel and adaptable packaging solution for albumin, the most common protein found in plasma—has experienced a threefold surge, ensuring a steady supply of this crucial plasma product.
- In August 2022, Terumo Blood and Cell Technologies, a medical technology company, announced that its new Rika Plasma Donation System successfully completed the first plasma donation in a plasma collection center, operated by CSL Plasma, a global leader in plasma collection.
- In September 2021, Grifols announced that TAVLESSE (fostamatinib), used to treat chronic immune thrombocytopenia (ITP) in adult patients refractory to other treatments, is available in France, Italy, and Spain and reimbursable from their respective health systems
U.S.: 
U.K. : 
India : 
